MARKET WIRE NEWS

LENZ Therapeutics Inc. (NASDAQ : LENZ) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.


Quote


Last:$4.175
Change Percent: 2.08%
Open:$4.15
Close:$4.175
High:$4.32
Low:$4.01
Volume:403,638
Last Trade Date Time:11/11/2026 03:45:38 pm

Stock Data


Market Cap:$427,420,977
Float:29,130,961
Insiders Ownership:0.22%
Institutions:43
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:https://www.graphitebio.com
Country:US
City:Solana Beach

Chart & Financials



Recent News Releases


Subscribe to Our Newsletter

**MWN-AI FAQ is based on asking OpenAI questions about LENZ Therapeutics Inc. (NASDAQ: LENZ).

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News